BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer - Lung Cancer
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Antonio Passaro on Twitter: "Great slides @ChristianRolfo on diagnostic challenges on MET amplification. #biomarker #lcsm #LungCancer… "
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.,Cancer Science - X-MOL
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. - Abstract - Europe PMC
FISH analysis of de novo MET amplification in advanced NSCLC and... | Download Scientific Diagram
Liquid biopsy data to detect METex14 changes and MET amplification in patients with advanced lung cancer are presented in the AACR - Onco Americas
Read in JCO:... - American Society of Clinical Oncology | Facebook
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Genes - Mass General Cancer Center
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification - European Journal of Cancer
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer | British Journal of Cancer
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
